# A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors

> **NCT05859464** · PHASE1 · TERMINATED · sponsor: **Zai Lab (Hong Kong), Ltd.** · enrollment: 34 (actual)

## Conditions studied

- Malignant Solid Tumor

## Interventions

- **DRUG:** ZL-1218
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05859464
- **Lead sponsor:** Zai Lab (Hong Kong), Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-07-24
- **Primary completion:** 2025-08-28
- **Final completion:** 2025-08-28
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-10-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05859464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05859464, "A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05859464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*